Novo Nordisk A/S (NYSE:NVO) surged 1.1% during the last session. The last traded price was up 0.57 points at $52.18. The data for the fund flow suggests that the net intraday money flow was $(-1.55) million. The fund value in upticks was recorded to be $5.93 million and in downticks, it was found to be $7.49 million. The up/down ratio for the day was measured to be 0.79. For the week, the shares have seen a percentage change of 1.7%.A block trade of $(-1.07) million in net money flow was also recorded during the day. For the block, the combined worth of upticks was $0 million and that of downticks was $1.07 million. The block tradeoff had the up/down ratio of 0.
The stock has recorded a 20-day Moving Average of 5.04% and the 50-Day Moving Average is 5.38%. The company shares have dropped 8.61% in the past 52 Weeks. On August 3, 2015 The shares registered one year high of $60.34 and one year low was seen on February 9, 2016 at $46.17. The 50-day moving average is $54.66 and the 200 day moving average is recorded at $54.75. S&P 500 has rallied 1.93% during the last 52-weeks.
Novo Nordisk A/S (NYSE:NVO): During Tuesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $52.47 and $51.91 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $52.50. The buying momentum continued till the end and the stock did not give up its gains. It closed at $52.15, notching a gain of 1.05% for the day. The total traded volume was 1,653,932 . The stock had closed at $51.61 on the previous day.
Institutional Investors own 7.48% of Novo Nordisk A/S shares.
Novo Nordisk A/S is a healthcare company. The Company is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. It has a range of diabetes product portfolio, including a portfolio of modern insulins as well as a human once-daily GLP-1 analog. It operates in two segments: diabetes care and biopharmaceuticals. The Companys diabetes care segment covers insulins, GLP-1, other protein-related products (such as glucagon, protein-related delivery systems and needles), oral anti-diabetic drugs and obesity. Its biopharmaceuticals segment covers the therapy areas of haemophilia care, growth hormone therapy and hormone replacement therapy. The primary production facilities owned by the Company are located at a number of sites in Denmark, and internationally in the United States, France, China and Brazil.